Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Dec 21, 2013; 19(47): 9012-9019
Published online Dec 21, 2013. doi: 10.3748/wjg.v19.i47.9012
Published online Dec 21, 2013. doi: 10.3748/wjg.v19.i47.9012
Table 2 1-, 5- and 10-year overall survival of patients with gastroenteropancreatic neuroendocrine tumors
Overall survival/period | Stomach | Small intestine | Pancreas | Appendix | Colon | Rectum |
1-yr/1976-1988 | 22% | 30% | 26% | 95% | 35% | 50% |
5-yr/1976-1988 | 11% | 18% | 11% | 92% | 16% | 37% |
10-yr/1976-1988 | 5% | 10% | 8% | 90% | 13% | 37% |
1-yr/1998-2006 | 71% | 85% | 74% | 95% | 68% | 74% |
5-yr/1998-2006 | 53% | 68% | 52% | 86% | 48% | 65% |
10-yr/1998-2006 | 43% | 53% | 35% | 81% | 34% | 50% |
- Citation: Scherübl H, Streller B, Stabenow R, Herbst H, Höpfner M, Schwertner C, Steinberg J, Eick J, Ring W, Tiwari K, Zappe SM. Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise: Epidemiological changes in Germany. World J Gastroenterol 2013; 19(47): 9012-9019
- URL: https://www.wjgnet.com/1007-9327/full/v19/i47/9012.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i47.9012